To describe trends in the regional and demographic characteristics of injection drug use (IDU) during pregnancy.
Methods:
Data were obtained from the Treatment Episode Data Set (TEDS), an administrative data set that captures admissions to federally funded treatment centers in the United States. Demographic and treatment-related measures were examined and compared between injection drug and noninjection drug admissions. The results were stratified by year of admission to assess trends over time.
Results:
From 1994 to 2006, there were 239,511 admissions of pregnant women, of whom 34,717 (14.4%) reported IDU. There was little change in the proportion of injecting from year to year. Compared with admissions of noninjecting pregnant women, a greater proportion of injection drug users were white (68.5 vs. 48.6%), reported heroin use (70.0% vs. 13.2%), and had no health insurance (48.2% vs. 40.2%). Over the time period, the proportion of injection drug users was seen to spread from the West to the South and Northeast for heroin and to the Midwest for amphetamines.
Conclusions:
IDU among pregnant women in drug treatment remains a significant public health issue, especially among white women.
Get full access to this article
View all access options for this article.
References
1.
Substance Abuse Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: National Findings. Rockville, MD, 2008.
2.
TienPC, KovacsA, BacchettiPet al.Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study. Clin Infect Dis, 2004; 39:1363–1370.
3.
Antiretroviral TherapyCC. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: Collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Synd, 2007; 46:607–615.
4.
JainV, YangMH, Kovacicova-LezcanoG, JuhleLS, BolgerAF, WinstonLG. Infective endocarditis in an urban medical center: Association of individual drugs with valvular involvement. J Infect, 2008; 57:132–138.
5.
PinkhamS, Malinowska-SempruchK. Women, harm reduction, and HIV. Reprod Health Matters, 2008; 16:168–181.
6.
MarlinkR, KaoH, HsiehE, GivingVT. Clinical care issues for women living with HIV and AIDS in the United States [Review]AIDS Res Hum Retrovir, 2001; 17:1–33.
7.
Center for Disease Control and Prevention. HIV/AIDS surveillance report, 2007Report No. 19Atlanta, GA: CDC, 2009.
8.
Centers for Disease Control and Prevention (CDC). HIV-associated behaviors among injecting-drug users—23 cities, United States, May 2005–February 2006. MMWR, 2009; 58:329–332.
9.
SchiffM, El-BasselN, EngstromM, GilbertL. Psychological distress and intimate physical and sexual abuse among women in methadone maintenance treatment programs. Soc Serv Rev, 2002; 76:302–320.
10.
RajahV. Respecting boundaries: The symbolic and material concerns of drug-involved women employing violence against violent male partners. Br J Criminol, 2006; 46:837–858.
11.
VelezML, MontoyaID, JanssonLMet al.Exposure to violence among substance-dependent pregnant women and their children. J Subst Abuse Treat, 2006; 30:31–38.
12.
BauerCR, ShankaranS, BadaHSet al.The Maternal Lifestyle Study: Drug exposure during pregnancy and short-term maternal outcomes. Am J Obstet Gynecol, 2002; 186:487–495.
13.
FinneganL. Clinical effects of pharmacologic agents on pregnancy, the fetus, and the neonate [Review]Ann NY Acad Sci, 1976; 281:74–89.
14.
Centers for Disease Control and Prevention. Cases of HIV infection and AIDS in the United States and dependent areas, by race/ethnicity, 2002–2006. HIV/AIDS Surveillance Supplemental Report 2008;13:1–43. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2008supp_vol13no1/.
15.
U.S. Department of Health and Human Services, Health Resources and Services Administration. Women's health USA 2004. Rockville, MD: U.S. Department of Health and Human Services, 2004.
16.
U.S. Department of Health and Human Services NIH. NIDA Research Report Series: Heroin abuse and addictionNIH publication number 05-41652005.
17.
WinklbaurB, KopfN, EbnerN, JungE, ThauK, FischerG. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: A knowledge synthesis for better treatment for women and neonates [Review]Addiction, 2008; 103:1429–1440.
18.
FoxK, MerrillJC, ChangHH, CalifanoJAJr. Estimating the costs of substance abuse to the Medicaid hospital care program. Am J Public Health, 1995; 85:48–54.
19.
BoydS. Mothers and illicit drugs: Transcending the myths. Toronto, Canada: University of Toronto Press, 1999.
OralR, StrangT. Neonatal illicit drug screening practices in Iowa: The impact of utilization of a structured screening protocol. J Perinatol, 2006; 26:660–666.
22.
ComfortM, LoverroJ, KaltenbachK. A search for strategies to engage women in substance abuse treatment. Soc Work Health Care, 2000; 31:59–70.
23.
JonesHE, SvikisDS, TranG. Patient compliance and maternal/infant outcomes in pregnant drug-using women. Subst Use Misuse, 2002; 37:1411–1422.
24.
HHS, SAMHSA, OAS. Treatment Episode Data Set (TEDS), 1994–2006. Synectics for Management Decisions II, ed. U.S.Dept.of Health and Human Services; Substance Abuse and Mental Health Services Administration; Office of Applied Studies. Ann Arbor, MI: Inter-university Consortium for Political and Social Research.
25.
SAMHSA. Treatment Episode Data Set (TEDS). Highlights—2005. National Admissions to Substance Abuse Treatment Services. Rockville, MDDHHS Publication No. (SMA) 07-42292006.
26.
GunterTD, ArndtS, WenmanG. Characteristics of admissions for primary stimulant dependence during 2001. Subst Use Misuse, 2006; 41:1277–1286.
27.
RosenbaumM. Women on heroin, 2nd. Newark, NJ: Rutgers University Press, 1981.
28.
NIDA. Drug addiction research and the health of women. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 1998.
29.
TerplanM, SmithEJ, KozloskiMJ, PollackHA. Methamphetamine use among pregnant women. Obstet Gynecol, 2009; 113:1285–1291.
30.
JonesHE, MartinPR, HeilSHet al.Treatment of opioid-dependent pregnant women: Clinical and research issues [Review]J Subst Abuse Treat, 2008; 35:245–259.
31.
McLellanAT, LewisDC, O'BrienCP, KleberHD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation [Review]JAMA, 2000; 284:1689–1695.
